Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The North America oral mucositis market was valued at USD 546.75 Million in 2025 and is expected to grow at a CAGR of 6.90%, reaching USD 1065.53 Million by 2035. The market is gaining traction with the introduction of advanced topical formulations and pain management solutions for cancer-induced mucositis. Enhanced focus on patient quality of life and rising healthcare expenditure are encouraging adoption. Ongoing research into anti-inflammatory and mucosal healing agents continues to support long-term growth across clinical settings.
Q1 2026 Market Updates
The Iran-US-Israel war that escalated in early 2026 is creating indirect but meaningful pressures on the North American oral mucositis treatment market, which dominates global market share at approximately 40 percent of worldwide revenue. North America benefits from a robust domestic pharmaceutical manufacturing infrastructure and relatively shorter supply chains for many oncology medications. However, the conflict's impact on global energy prices, with Brent crude surging past USD 120 per barrel, is inflating production costs for pharmaceutical manufacturers and healthcare delivery systems alike.
Pharmaceutical input costs have risen an estimated 20 to 30 percent as petrochemical-derived excipients, drug packaging materials, and energy costs escalate. While North American pharmaceutical supply chains are less directly exposed to the Strait of Hormuz disruption than those in Asia or Europe, the interconnected nature of global pharmaceutical ingredient sourcing means that price inflation propagates across all markets. Key oral mucositis treatments including palifermin and benzydamine mouthwashes rely on complex API supply chains with global touchpoints. The FDA-designated Breakthrough Therapy avasopasem, a promising new treatment for radiation-induced oral mucositis, faces potential cost escalation during its commercial launch phase.
North American healthcare spending is substantial but increasingly under cost management pressure. The OECD's forecast of 4 percent global inflation is affecting hospital pharmacy budgets and insurance reimbursement dynamics. Cancer treatment centres that manage oral mucositis as part of comprehensive oncology care face the dual challenge of rising drug costs and increased patient volumes. The IEA's largest-ever emergency oil stock release on 11 March 2026 demonstrates the severity of energy market disruption, though it may help moderate pharmaceutical production cost inflation.
The Pentagon's identification of 13 critical minerals essential for advanced technologies underscores broader supply chain vulnerabilities, though pharmaceutical applications are less directly affected. The G7's 30 March 2026 pledge to safeguard supply chains may help stabilise pharmaceutical logistics. North American pharmaceutical companies should leverage their domestic manufacturing strength while ensuring continued API supply chain diversification. The region's innovation pipeline, including avasopasem's advancement through clinical development, positions North America to maintain leadership in oral mucositis treatment despite the global economic headwinds from the conflict.
Key Takeaways
Government:
- The FDA's Breakthrough Therapy and Fast Track Designations for avasopasem demonstrate continued regulatory support for oral mucositis treatment innovation despite the conflict-driven economic environment.
- The IEA's emergency oil release on 11 March 2026 may help moderate energy-driven pharmaceutical production cost inflation affecting North American oral mucositis drug manufacturers.
- The G7's 30 March 2026 supply chain pledge supports North America's pharmaceutical logistics stability, though domestic manufacturing infrastructure provides inherent resilience.
Market:
- North America dominates the global oral mucositis market at 40 percent revenue share, but pharmaceutical input costs surging 20 to 30 percent are inflating treatment costs across the region.
- Brent crude at USD 120 per barrel is driving up petrochemical excipient and packaging costs, while the OECD's 4 percent inflation forecast pressures hospital pharmacy budgets and reimbursement dynamics.
- Avasopasem's commercial launch phase faces potential cost escalation from conflict-driven pharmaceutical input inflation, despite strong clinical development momentum.
Procurement:
- North American pharmaceutical supply chains benefit from domestic manufacturing strength but remain exposed to global API sourcing price inflation driven by the Middle East conflict.
- Hospital pharmacy budgets face cost management pressure as oral mucositis treatment costs rise alongside broader pharmaceutical price inflation.
- Procurement teams should negotiate volume-based pricing agreements with domestic manufacturers, diversify API supply sources, and establish strategic safety stocks for critical oral mucositis treatments.
Key Market Trends and Insights
- By drug class, the antibiotics segment is projected to lead the market during the forecast period.
- Based on end user, the hospitals and clinics segment is anticipated to capture the major market share during the forecast period.
- By distribution channel, the hospital pharmacies dominated the market during the historical period, accounting for over 80% of total revenue.
Market Size and Forecast
- Market Size (2025): USD 546.75 Million
- Projected Market Size (2035): USD 1065.53 Million
- CAGR (2026-2035): 6.90%
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
-
In the United States, an estimated 500,000–1,000,000 patients develop oral mucositis annually, significantly driving market growth as the rising incidence among cancer patients increases the demand for effective therapeutic and preventive treatments.
-
In November 2023, BioSyent Pharma Inc. launched Gelclair® in Canada for relieving oral mucositis pain in cancer patients. The product’s approval and availability are expected to enhance treatment accessibility and drive market growth across North America.
-
The market is experiencing steady growth driven by rising cancer cases, increasing adoption of advanced therapeutic solutions, and strong contributions from key players focusing on innovative treatment options and improved patient care outcomes.
Compound Annual Growth Rate
6.9%
Value in USD Million
2026-2035
*this image is indicative*
North America Oral Mucositis Market Overview
Oral mucositis frequently develops as a side effect of cancer therapies, causing severe pain and difficulty in eating or speaking. In North America, the market was valued at USD 546.75 Million in 2025. It is growing steadily, supported by increasing cancer incidence, a strong focus on patient-centric care, and expanded use of advanced therapeutic interventions. Ongoing research collaborations, improved access to preventive solutions, and technological innovations in phototherapy and mucosal healing products are strengthening the region’s market performance and clinical adoption rates.
North America Oral Mucositis Market Growth Drivers
Rising Cancer Incidence to Drive the Market Growth in North America
The growing incidence of cancer across North America is a key driver of the oral mucositis market. For instance, in January 2025, PubMed Central reported that approximately 2,041,910 new invasive cancer cases are projected to be diagnosed in the United States, averaging about 5,600 cases daily. As chemotherapy and radiotherapy remain integral to cancer management, the associated risk of oral mucositis is increasing significantly. This surge in oncology cases is expected to elevate the demand for effective oral mucositis prevention and treatment solutions, thereby strengthening market growth across the region.
North America Oral Mucositis Market Trends
Some of the key trends in the market include advancements in oral cryotherapy devices and the development of innovative therapeutic approaches.
Strategic Collaborations Boosting the Market Value
Strategic collaborations are driving the adoption of advanced oral cryotherapy technologies aimed at alleviating chemotherapy-induced mucosal damage, thereby enhancing the overall market value. In September 2024, the collaboration between Sanara MedTech Inc. and InfuSystem Holdings, Inc. exemplified this trend through the exclusive U.S. distribution of an FDA-cleared oral cryotherapy device designed to reduce the severity of oral mucositis. The increasing adoption of such clinically validated and reimbursable therapeutic solutions is anticipated to enhance patient outcomes and significantly boost market growth in the coming years.
Increasing Therapeutic Innovations Bolstering the North America Oral Mucositis Market Demand
The market is witnessing an increasing focus on developing targeted therapies aimed at reducing the adverse effects of cancer treatments. In June 2024, clinical progress surrounding ST-617 by Supportive Therapeutics highlighted growing research interest in novel formulations designed to prevent and treat chemotherapy- and radiation-induced oral mucositis. Such advancements reflect a broader industry shift toward precision-driven supportive care, enhancing patient outcomes and quality of life. This innovation-driven momentum is expected to significantly boost market growth in the coming years.
North America Oral Mucositis Market Share
Antibiotics Expected to Dominate the Market Share by Drug Class
The market is segmented by drug class into antibiotics, antifungal, anti-inflammatory, anti-neoplastic, and others. Each category contributes to managing infection, inflammation, and tissue damage during treatment. Among these, the antibiotics segment is anticipated to lead the market, driven by their essential role in preventing and treating secondary bacterial infections that commonly accompany mucosal damage. The growing use of broad-spectrum antibiotics and preventive antimicrobial therapies further supports their leading position in clinical management.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
North America Oral Mucositis Market Analysis by Region
The market is divided into regions such as the United States and Canada. Among these, the United States market is expected to dominate, driven by high cancer prevalence and growing adoption of innovative supportive care products. In October 2024, Jaguar Health launched Gelclair, an FDA-approved oral mucositis prescription product through its subsidiary Napo Pharmaceuticals. This launch underscores the country’s strong focus on improving cancer supportive care. Gelclair’s introduction reflects the U.S. leadership in advancing effective pain management and quality-of-life solutions for oncology patients.
Leading Players in the North America Oral Mucositis Market
The key features of the market report comprise funding and investment analysis, clinical trials and pipeline analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen Inc.
Amgen Inc. is a significant player in the market and has strengthened its position through the approval and clinical success of Kepivance (palifermin). This therapy mitigates severe oral mucositis among patients with hematologic malignancies receiving intensive chemotherapy or radiation. The company’s science-driven approach and patient-centered innovations continue to support the region’s oncology care advancements and therapeutic outcomes.
Innovation Pharmaceuticals Inc.
Innovation Pharmaceuticals is actively involved in the market. In its Phase 2 clinical trial, the company reported that Brilacidin-OM markedly reduced the incidence of oral mucositis in patients recieving high-dose cisplatin therapy. The firm emphasizes statistically significant subgroup findings and acceptable safety profiles. With an FDA Fast Track designation and subsequent analysis informing study design, the company is pursuing regulatory and reimbursement pathways across North America. It is also assessing commercialization strategies to address an unmet clinical need for effective severe oral mucositis prevention.
Galera Therapeutics Inc.
Galera Therapeutics Inc. plays a vital role in advancing oncology supportive care through its innovative drug development. The company focuses on radiotherapy-induced toxicities, particularly oral mucositis, a serious condition affecting cancer patients undergoing radiation treatment. With its research-driven approach and expanding clinical programs, Galera aims to deliver effective and safe therapies that enhance patient comfort, reduce complications, and complement existing cancer treatment protocols.
Soligenix Inc.
Soligenix Inc. plays a key role in advancing oncology care through its focus on oral mucositis and related inflammatory conditions. The company’s work centers on strengthening immune defense and accelerating recovery for patients undergoing cancer therapy. Its commitment to scientific innovation and collaboration with clinical networks in the region reflects an effort to deliver effective therapeutic options for managing treatment-induced mucosal damage.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Monopar Therapeutics Inc., Oragenics Inc., Jaguar Health Inc., EpicentRx Inc., and Enzychem Lifesciences.
North America Oral Mucositis Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
- Antibiotics
- Antifungal
- Anti-Inflammatory
- Anti-Neoplastic
- Others
Market Breakup by End User
- Hospitals and Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Country
- United States
- Canada
Key Questions Answered in the North America Oral Mucositis Market Report
- What was the North America oral mucositis market value in 2025?
- What is the North America oral mucositis market forecast outlook for 2026-2035?
- What are the major factors aiding the North America oral mucositis market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major North America oral mucositis market trends?
- Which drug class is expected to dominate the market segment?
- Which end user is projected to lead the market segment?
- Which distribution channel is anticipated to drive the market segment?
- Who are the key players involved in the North America oral mucositis market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Pricing Plans
Upto 15% Off
USD
-
$2699 $2429
-
$4299 $3869
-
$5799 $4949
-
$6999 $5949
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Country |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share